Meeshanthini Dogan - Cardio Diagnostics CEO CoFounder
| CDIO Stock | USD 0.43 0 0.40% |
Insider
Meeshanthini Dogan is CEO CoFounder of Cardio Diagnostics Holdings
| Age | 36 |
| Address | 311 West Superior Street, Chicago, IL, United States, 60654 |
| Phone | 302 281 2147 |
| Web | https://cardiodiagnosticsinc.com |
Meeshanthini Dogan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Meeshanthini Dogan against Cardio Diagnostics stock is an integral part of due diligence when investing in Cardio Diagnostics. Meeshanthini Dogan insider activity provides valuable insight into whether Cardio Diagnostics is net buyers or sellers over its current business cycle. Note, Cardio Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cardio Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Meeshanthini Dogan over two months ago Acquisition by Meeshanthini Dogan of 272250 shares of Cardio Diagnostics at 1.26 subject to Rule 16b-3 | ||
Meeshanthini Dogan over six months ago Acquisition by Meeshanthini Dogan of 68965 shares of Cardio Diagnostics at 0.29 subject to Rule 16b-3 | ||
Meeshanthini Dogan over a year ago Acquisition by Meeshanthini Dogan of 476256 shares of Cardio Diagnostics subject to Rule 16b-3 | ||
Meeshanthini Dogan over a year ago Purchase by Meeshanthini Dogan of 1770 shares of Cardio Diagnostics |
Cardio Diagnostics Management Efficiency
The company has return on total asset (ROA) of (1.0043) % which means that it has lost $1.0043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.763) %, meaning that it created substantial loss on money invested by shareholders. Cardio Diagnostics' management efficiency ratios could be used to measure how well Cardio Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to drop to -2.02. In addition to that, Return On Capital Employed is likely to drop to -0.88. At this time, Cardio Diagnostics' Total Assets are very stable compared to the past year. As of the 25th of March 2025, Net Tangible Assets is likely to grow to about 929.3 K, while Non Current Assets Total are likely to drop about 964.4 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Debra Nielsen | Immunocore Holdings | N/A | |
| Jean Franchi | Replimune Group | 58 | |
| Michael Fischbach | Revolution Medicines | 44 | |
| Troy JD | Avidity Biosciences | 56 | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| Alexander Kuta | Uniqure NV | 64 | |
| Prof Davis | Avidity Biosciences | N/A | |
| Pr Katus | Uniqure NV | N/A | |
| Maria Cantor | Uniqure NV | 56 | |
| Margaret JD | Revolution Medicines | 62 | |
| MD MBA | Pliant Therapeutics | 48 | |
| Annelise Vuidepot | Immunocore Holdings | N/A | |
| Hal MD | Pliant Therapeutics | N/A | |
| CPA CPA | Rocket Pharmaceuticals | 51 | |
| Bahija Jallal | Immunocore Holdings | 64 | |
| Matthew Kapusta | Uniqure NV | 52 | |
| Michael Flanagan | Avidity Biosciences | 62 | |
| Christian Klemt | Uniqure NV | 52 | |
| Sbastien Desprez | Immunocore Holdings | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Peter MBA | Mirum Pharmaceuticals | 47 | |
Management Performance
| Return On Equity | -2.76 | ||||
| Return On Asset | -1.0 |
Cardio Diagnostics Leadership Team
Elected by the shareholders, the Cardio Diagnostics' board of directors comprises two types of representatives: Cardio Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardio. The board's role is to monitor Cardio Diagnostics' management team and ensure that shareholders' interests are well served. Cardio Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardio Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Esq JD, Chief Officer | ||
| Timur Dogan, Chief Officer | ||
| Meeshanthini Dogan, CEO CoFounder | ||
| Khullani JD, Vice Strategy | ||
| MBA JD, CFO Director |
Cardio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardio Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.76 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (214.13) % | ||||
| Current Valuation | 16.3 M | ||||
| Shares Outstanding | 52.15 M | ||||
| Shares Owned By Insiders | 7.68 % | ||||
| Shares Owned By Institutions | 4.90 % | ||||
| Number Of Shares Shorted | 2.52 M | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 631.36 X |
Pair Trading with Cardio Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardio Stock
Moving against Cardio Stock
| 0.82 | GE | GE Aerospace | PairCorr |
| 0.75 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.75 | WM | Waste Management | PairCorr |
| 0.6 | LUCD | Lucid Diagnostics | PairCorr |
| 0.45 | MLSS | Milestone Scientific Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.31) | Revenue Per Share | Quarterly Revenue Growth (0.34) | Return On Assets | Return On Equity |
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.